Nanomedicine: Nanotechnology, Biology and Medicine
Volume 8, Issue 2 , Pages 185-193 , February 2012

Novel nanostructured lipid-dextran sulfate hybrid carriers overcome tumor multidrug resistance of mitoxantrone hydrochloride

  • Peng Zhang, PhD

      Affiliations

    • School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
    • ,
  • Guixia Ling, PhD

      Affiliations

    • School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
    • ,
  • Xiaolei Pan, MS

      Affiliations

    • School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
    • ,
  • Jin Sun, PhD

      Affiliations

    • School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
    • ,
  • Tianhong Zhang, PhD

      Affiliations

    • School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
    • ,
  • Xiaohui Pu, PhD

      Affiliations

    • School of Pharmacy, Henan University, Kaifeng, China
    • ,
  • Shiliang Yin, PhD

      Affiliations

    • School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
    • ,
  • Zhonggui He, PhD

      Affiliations

    • School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
    • Corresponding Author InformationCorresponding author: School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China.

Received 3 March 2011 ,Accepted 7 June 2011.

References 

  1. Stein WD, Bates SE, Fojo T. Intractable cancers: the many faces of multidrug resistance and the many targets it presents for therapeutic attack. Curr Drug Targets. 2004;5:333–346
  2. Bolhuis H, Veen HW, Poolman B, Driessen AJM, Konings WN. Mechanism of multidrug transporters. FEMS Microbiol Rev. 1997;21:55–84
  3. Dean M, Allikmets R. Complete characterization of the human ABC gene family. J Bioenerg Biomembr. 2001;33:475–479
  4. Doughty JC, Kane E, Cooke TG, McArdle CS. Mitoxantrone and methotrexate chemotherapy with and without mitomycin C in the regional treatment of locally advanced breast cancer. Breast. 2002;11:97–99
  5. Khalaf A, Pfister C, Hellot MF, Dunet F, Moussu J, Grise P. Value of mitoxantrone in metastatic hormone-resistant prostate cancer. Prog Urol. 2002;12:37–42
  6. Hagemeister F, Cabanillas F, Coleman M, Gregory SA, Zinzani PL. The role of mitoxantrone in the treatment of indolent lymphomas. Oncologist. 2005;10:150–159
  7. Novoselac AV, Reddy S, Sanmugarajah J. Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone. Leukemia. 2004;18:1561–1562
  8. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA. 1998;95:15665–15670
  9. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res. 1999;59:4559–4563
  10. Kang KW, Chun MK, Kim O, Subedi RK, Ahn SG, Yoon JH, et al. Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomed Nanotechnol Biol Med. 2010;6:210–213
  11. Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 2002;242:121–128
  12. Ricci M, Puglia C, Bonina F, Di Giovanni C, Giovagnoli S, Rossi C. Evaluation of indomethacin percutaneous absorption from nanostructured lipid carriers (NLC): in vitro and in vivo studies. J Pharm Sci. 2005;94:1149–1159
  13. Yuan H, Wang LL, Du YZ, You J, Hu FQ, Zeng S. Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification. Colloids Surf B Biointerfaces. 2007;60:174–179
  14. Zhang P, Ling G, Sun J, Sun Y, Pu X, Wang Z, et al. Determination of mitoxantrone in rat plasma by liquid chromatography-tandem mass spectrometry method: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878:2260–2265
  15. Li Y, Wong HL, Shuhendler AJ, Rauth AM, Wu XY. Molecular interactions, internal structure and drug release kinetics of rationally developed polymer–lipid hybrid nanoparticles. J Control Release. 2008;128:60–70
  16. Wong HL, Rauth AM, Bendayan R, Manias JL, Ramaswamy M, Liu Z, et al. A new polymer–lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res. 2006;23:1574–1585
  17. Wong HL, Bendayan R, Rauth AM, Wu XY. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer–lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Control Release. 2006;116:275–284
  18. Yuan X, Shah BA, Kotadia NK, Li J, Gu H, Wu Z. The development and mechanism studies of cationic chitosan-modified biodegradable PLGA nanoparticles for efficient siRNA drug delivery. Pharm Res. 2010;27:1285–1295
  19. Paillard A, Passirani C, Saulnier P, Kroubi M, Garcion E, Benoît JP, et al. Positively-charged, porous, polysaccharide nanoparticles loaded with anionic molecules behave as ‘stealth’ cationic nanocarriers. Pharm Res. 2010;27:126–133
  20. Wang Y, Wang R, Lu X, Lu W, Zhang C, Liang W. Pegylated phospholipids-based self-assembly with water-soluble drugs. Pharm Res. 2010;27:361–370
  21. Ling G, Zhang P, Zhang W, Sun J, Meng X, Qin Y, et al. Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition. J Control Release. 2010;148:241–248
  22. Faulds D, Balfour JA, Chrisp P, Langtry HD. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs. 1991;41:400–449
  23. Schwendener RA, Horber DH, Rentsch K, Hänseler E, Pestalozzi B, Sauter C. Preclinical and clinical experience with liposome-encapsulated mitoxantrone. J Liposome Res. 1994;4:605–639
  24. Jain KK. Evaluation of mitoxantrone for the treatment of multiple sclerosis. Expert Opin Invest Drugs. 2000;9:1139–1149
  25. Wong HL, Bendayan R, Rauth AM, Xue HY, Babakhanian K, Wu XY. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J Pharmacol Exp Ther. 2006;317:1372–1381
  26. Chen L, Li H, Zhao R, Zhu JW. Study progress of cell endocytosis. Chin Germ J Clin Oncol. 2009;8:360–365

 The work was supported by the National Basic Research Program of China (973 Program), No. 2009CB930300, and Key Project for Drug Innovation (2008ZX09401-004) from the Ministry of Science and Technology of China.

PII: S1549-9634(11)00260-7

doi: 10.1016/j.nano.2011.06.007

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 8, Issue 2 , Pages 185-193 , February 2012

Article Tools

* Image Usage & Resolution